CRL
Charles River Laboratories Inte
Price Chart
Latest Quote
$228.53
-0.60 (-0.26%)
Current Price
| Previous Close | $229.13 |
| Open | $224.94 |
| Day High | $228.53 |
| Day Low | $222.67 |
| Volume | 47,850 |
Stock Information
| Shares Outstanding | 48.17M |
| Total Debt | $3.06B |
| Cash Equivalents | $191.83M |
| Revenue | $4.03B |
| Net Income | $-184.65M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $10.81B |
| EPS (TTM) | $-3.70 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $13.73B |
| Sales | $4.03B |
| Income | $-184.65M |
| Book/sh | $61.05 |
| Cash/sh | $3.98 |
| Employees | 18K |
Financial Ratios
| Quick Ratio | 0.82 |
| Current Ratio | 1.36 |
| Debt/Eq | 102.55 |
Returns & Margins
| ROA | 4.26% |
| ROE | -5.87% |
| Gross Margin | 34.46% |
| Operating Margin | 15.92% |
| Profit Margin | -4.58% |
Ownership
| Insider Ownership | 0.64% |
| Institutional Ownership | 123.34% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 18.20 |
| PEG | 0.12 |
| P/S | 2.68 |
| P/B | 3.67 |
Analyst Data
| Recommendation | buy |
| Target Price | $230.93 |
Technical Indicators
| SMA20 | $219.48 |
| SMA50 | $191.98 |
| SMA200 | $184.35 |
| RSI | 59.18 |
| ATR | 8.5607 |
| Shares Float | 47.65M |
| Short Float | 10.43% |
| Short Ratio | 5.13 |
| Volatility | 1.40 |
| Rel Volume | 0.77 |
Performance History
| Week | -3.88% |
| Month | +21.41% |
| Quarter | +26.79% |
| 6 Months | +3.68% |
| YTD | +10.83% |
| Year | +44.80% |
| 3 Years | +6.33% |
| 5 Years | -41.71% |
| 10 Years | +163.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $224.35 | 710,200 |
| 2026-07-16 | $229.16 | 911,500 |
| 2026-07-15 | $228.22 | 860,600 |
| 2026-07-14 | $231.21 | 964,700 |
| 2026-07-13 | $229.75 | 910,100 |
| 2026-07-10 | $233.41 | 873,200 |
| 2026-07-09 | $233.60 | 652,900 |
| 2026-07-08 | $223.96 | 740,800 |
| 2026-07-07 | $228.68 | 806,400 |
| 2026-07-06 | $231.43 | 631,900 |
| 2026-07-02 | $230.69 | 845,300 |
| 2026-07-01 | $229.09 | 1,086,100 |
| 2026-06-30 | $226.79 | 1,061,300 |
| 2026-06-29 | $225.57 | 1,091,700 |
| 2026-06-26 | $215.75 | 1,445,800 |
| 2026-06-25 | $212.71 | 1,536,000 |
| 2026-06-24 | $202.10 | 936,600 |
| 2026-06-23 | $186.60 | 632,100 |
| 2026-06-22 | $181.56 | 670,100 |
| 2026-06-18 | $185.00 | 1,170,100 |
About Charles River Laboratories Inte
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
đ° Latest News
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
Zacks âĸ 2026-07-17T16:00:02Z
Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued?
Simply Wall St. âĸ 2026-07-17T04:33:14Z
Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
Zacks âĸ 2026-07-16T15:50:00Z
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-07-16T13:40:02Z
Does Arovella CAR-iNKT NGS Partnership Deepen Charles Riverâs Cell Therapy Moat or Stretch CRL Too Thin?
Simply Wall St. âĸ 2026-07-16T10:11:32Z
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Zacks âĸ 2026-07-14T16:10:05Z
ICON Stock and the CRO Trends Shaping Its Next Growth Phase
Zacks âĸ 2026-07-08T18:09:00Z
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026
Zacks âĸ 2026-07-07T13:52:00Z
3 Overrated Stocks Weâre Skeptical Of
StockStory âĸ 2026-07-07T11:37:52Z
Medpace Stock Outlook Turns on Backlog Quality and Cancellations
Zacks âĸ 2026-07-06T14:00:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,467,861,000 | $2,494,898,000 | $2,450,169,000 | $2,356,117,000 |
| Cost Of Revenue | $2,692,107,000 | $2,718,168,000 | $2,626,853,000 | $2,513,409,000 |
| Total Revenue | $4,015,382,000 | $4,049,989,000 | $4,129,409,000 | $3,976,060,000 |
| Operating Revenue | $4,015,382,000 | $4,049,989,000 | $4,129,409,000 | $3,976,060,000 |
| Expenses | ||||
| Interest Expense | $107,029,000 | $126,288,000 | $136,710,000 | $59,291,000 |
| Total Expenses | $3,614,246,000 | $3,607,642,000 | $3,512,148,000 | $3,325,085,000 |
| Other Income Expense | $-398,550,000 | $-231,520,000 | $95,537,000 | $30,523,000 |
| Other Non Operating Income Expenses | $-22,576,000 | $-16,520,000 | $95,537,000 | $30,523,000 |
| Net Non Operating Interest Income Expense | $-102,089,000 | $-117,713,000 | $-131,514,000 | $-58,511,000 |
| Interest Expense Non Operating | $107,029,000 | $126,288,000 | $136,710,000 | $59,291,000 |
| Operating Expense | $922,139,000 | $889,474,000 | $885,295,000 | $811,676,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-144,338,000 | $10,297,000 | $474,624,000 | $486,226,000 |
| Net Interest Income | $-102,089,000 | $-117,713,000 | $-131,514,000 | $-58,511,000 |
| Interest Income | $4,940,000 | $8,575,000 | $5,196,000 | $780,000 |
| Normalized Income | $152,681,460 | $180,147,000 | $474,624,000 | $486,226,000 |
| Net Income From Continuing And Discontinued Operation | $-144,338,000 | $10,297,000 | $474,624,000 | $486,226,000 |
| Total Operating Income As Reported | $25,162,000 | $227,347,000 | $617,261,000 | $650,975,000 |
| Net Income Common Stockholders | $-144,338,000 | $10,297,000 | $474,624,000 | $486,226,000 |
| Net Income | $-144,338,000 | $10,297,000 | $474,624,000 | $486,226,000 |
| Net Income Including Noncontrolling Interests | $-142,163,000 | $25,291,000 | $480,370,000 | $492,608,000 |
| Net Income Continuous Operations | $-142,163,000 | $25,291,000 | $480,370,000 | $492,608,000 |
| Pretax Income | $-99,503,000 | $93,114,000 | $581,284,000 | $622,987,000 |
| Special Income Charges | $-375,974,000 | $-215,000,000 | $0 | $0 |
| Interest Income Non Operating | $4,940,000 | $8,575,000 | $5,196,000 | $780,000 |
| Operating Income | $401,136,000 | $442,347,000 | $617,261,000 | $650,975,000 |
| Depreciation Amortization Depletion Income Statement | $179,066,000 | $138,471,000 | $137,440,000 | $146,578,000 |
| Depreciation And Amortization In Income Statement | $179,066,000 | $138,471,000 | $137,440,000 | $146,578,000 |
| Amortization Of Intangibles Income Statement | $179,066,000 | $138,471,000 | $137,440,000 | $146,578,000 |
| Gross Profit | $1,323,275,000 | $1,331,821,000 | $1,502,556,000 | $1,462,651,000 |
| Per Share | ||||
| Diluted EPS | $-2.91 | $0.20 | $9.22 | $9.48 |
| Basic EPS | $-2.91 | $0.20 | $9.27 | $9.57 |
| Other | ||||
| Tax Effect Of Unusual Items | $-78,954,540 | $-45,150,000 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $786,812,000 | $796,143,000 | $1,032,118,000 | $986,148,000 |
| Total Unusual Items | $-375,974,000 | $-215,000,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-375,974,000 | $-215,000,000 | $0 | $0 |
| Reconciled Depreciation | $403,312,000 | $361,741,000 | $314,124,000 | $303,870,000 |
| EBITDA (Bullshit earnings) | $410,838,000 | $581,143,000 | $1,032,118,000 | $986,148,000 |
| EBIT | $7,526,000 | $219,402,000 | $717,994,000 | $682,278,000 |
| Diluted Average Shares | $49,564,000 | $51,628,000 | $51,451,000 | $51,301,000 |
| Basic Average Shares | $49,564,000 | $51,380,000 | $51,227,000 | $50,812,000 |
| Diluted NI Availto Com Stockholders | $-144,338,000 | $10,297,000 | $474,624,000 | $486,226,000 |
| Minority Interests | $-2,175,000 | $-14,994,000 | $-5,746,000 | $-6,382,000 |
| Tax Provision | $42,660,000 | $67,823,000 | $100,914,000 | $130,379,000 |
| Impairment Of Capital Assets | $375,974,000 | $215,000,000 | $0 | $0 |
| Amortization | $179,066,000 | $138,471,000 | $137,440,000 | $146,578,000 |
| Selling General And Administration | $743,073,000 | $751,003,000 | $747,855,000 | $665,098,000 |
| Otherunder Preferred Stock Dividend | - | $11,906,000 | $0 | $0 |
Fetched: 2026-07-08
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $60,382,000 | $-108,505,000 | $-362,214,000 | $-828,885,000 |
| Total Assets | $7,135,422,000 | $7,528,345,000 | $8,195,001,000 | $7,602,770,000 |
| Total Non Current Assets | $5,688,373,000 | $6,125,274,000 | $6,586,339,000 | $6,163,738,000 |
| Other Non Current Assets | $293,185,000 | $278,233,000 | $309,383,000 | $148,279,000 |
| Non Current Deferred Assets | $67,334,000 | $42,179,000 | $40,279,000 | $41,262,000 |
| Non Current Deferred Taxes Assets | $67,334,000 | $42,179,000 | $40,279,000 | $41,262,000 |
| Goodwill And Other Intangible Assets | $3,104,248,000 | $3,570,008,000 | $3,959,096,000 | $3,805,178,000 |
| Other Intangible Assets | $339,995,000 | $723,400,000 | $864,051,000 | $955,275,000 |
| Current Assets | $1,447,049,000 | $1,403,071,000 | $1,608,662,000 | $1,439,032,000 |
| Other Current Assets | $129,212,000 | $105,796,000 | $83,378,000 | $107,580,000 |
| Prepaid Assets | $96,108,000 | $103,210,000 | $87,879,000 | $89,341,000 |
| Inventory | $299,103,000 | $278,544,000 | $380,259,000 | $255,809,000 |
| Receivables | $708,856,000 | $720,915,000 | $780,375,000 | $752,390,000 |
| Receivables Adjustments Allowances | $-10,463,000 | $-18,301,000 | $-25,722,000 | $-11,278,000 |
| Other Receivables | $200,591,000 | $211,511,000 | $228,020,000 | $204,258,000 |
| Accounts Receivable | $518,728,000 | $527,705,000 | $578,077,000 | $559,410,000 |
| Cash Cash Equivalents And Short Term Investments | $213,770,000 | $194,606,000 | $276,771,000 | $233,912,000 |
| Cash And Cash Equivalents | $213,770,000 | $194,606,000 | $276,771,000 | $233,912,000 |
| Non Current Accounts Receivable | - | - | - | - |
| Restricted Cash | - | - | - | - |
| Debt | ||||
| Net Debt | $1,897,942,000 | $2,019,929,000 | $2,370,376,000 | $2,473,619,000 |
| Total Debt | $2,570,408,000 | $2,723,994,000 | $3,066,381,000 | $3,097,276,000 |
| Long Term Debt And Capital Lease Obligation | $2,570,408,000 | $2,723,994,000 | $3,066,381,000 | $3,097,276,000 |
| Long Term Debt | $2,111,712,000 | $2,214,535,000 | $2,647,147,000 | $2,707,531,000 |
| Current Debt And Capital Lease Obligation | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,924,228,000 | $4,020,267,000 | $4,536,003,000 | $4,579,265,000 |
| Total Non Current Liabilities Net Minority Interest | $2,803,913,000 | $3,026,166,000 | $3,480,921,000 | $3,487,680,000 |
| Other Non Current Liabilities | $138,302,000 | $195,212,000 | $223,191,000 | $174,822,000 |
| Non Current Deferred Liabilities | $95,203,000 | $106,960,000 | $191,349,000 | $215,582,000 |
| Non Current Deferred Taxes Liabilities | $95,203,000 | $106,960,000 | $191,349,000 | $215,582,000 |
| Current Liabilities | $1,120,315,000 | $994,101,000 | $1,055,082,000 | $1,091,585,000 |
| Other Current Liabilities | $222,158,000 | $194,014,000 | $203,210,000 | $204,575,000 |
| Current Deferred Liabilities | $210,418,000 | $248,322,000 | $241,820,000 | $264,259,000 |
| Payables And Accrued Expenses | $418,885,000 | $372,347,000 | $396,762,000 | $425,673,000 |
| Payables | $148,800,000 | $140,337,000 | $168,937,000 | $205,915,000 |
| Accounts Payable | $148,800,000 | $140,337,000 | $168,937,000 | $205,915,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Total Tax Payable | - | - | - | - |
| Income Tax Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $3,164,630,000 | $3,461,503,000 | $3,596,882,000 | $2,976,293,000 |
| Total Equity Gross Minority Interest | $3,211,194,000 | $3,508,078,000 | $3,658,998,000 | $3,023,505,000 |
| Stockholders Equity | $3,164,630,000 | $3,461,503,000 | $3,596,882,000 | $2,976,293,000 |
| Gains Losses Not Affecting Retained Earnings | $-171,783,000 | $-317,345,000 | $-196,427,000 | $-262,057,000 |
| Other Equity Adjustments | $-171,783,000 | $-317,345,000 | $-196,427,000 | $-262,057,000 |
| Retained Earnings | $1,388,620,000 | $1,812,100,000 | $1,887,218,000 | $1,432,901,000 |
| Long Term Equity Investment | $206,972,000 | $218,350,000 | $243,811,000 | $311,602,000 |
| Other | ||||
| Treasury Shares Number | $0 | $0 | $0 | $0 |
| Ordinary Shares Number | $49,217,000 | $51,141,000 | $51,338,000 | $50,944,000 |
| Share Issued | $49,217,000 | $51,141,000 | $51,338,000 | $50,944,000 |
| Tangible Book Value | $60,382,000 | $-108,505,000 | $-362,214,000 | $-828,885,000 |
| Invested Capital | $5,276,342,000 | $5,676,038,000 | $6,244,029,000 | $5,683,824,000 |
| Working Capital | $326,734,000 | $408,970,000 | $553,580,000 | $347,447,000 |
| Capital Lease Obligations | $458,696,000 | $509,459,000 | $419,234,000 | $389,745,000 |
| Total Capitalization | $5,276,342,000 | $5,676,038,000 | $6,244,029,000 | $5,683,824,000 |
| Minority Interest | $46,564,000 | $46,575,000 | $62,116,000 | $47,212,000 |
| Treasury Stock | $0 | $0 | $0 | $0 |
| Additional Paid In Capital | $1,947,301,000 | $1,966,237,000 | $1,905,578,000 | $1,804,940,000 |
| Capital Stock | $492,000 | $511,000 | $513,000 | $509,000 |
| Common Stock | $492,000 | $511,000 | $513,000 | $509,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $458,696,000 | $509,459,000 | $419,234,000 | $389,745,000 |
| Current Deferred Revenue | $210,418,000 | $248,322,000 | $241,820,000 | $264,259,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $268,854,000 | $179,418,000 | $213,290,000 | $197,078,000 |
| Current Accrued Expenses | $270,085,000 | $232,010,000 | $227,825,000 | $219,758,000 |
| Investments And Advances | $206,972,000 | $218,350,000 | $243,811,000 | $311,602,000 |
| Goodwill | $2,764,253,000 | $2,846,608,000 | $3,095,045,000 | $2,849,903,000 |
| Net PPE | $2,016,634,000 | $2,016,504,000 | $2,033,770,000 | $1,857,417,000 |
| Accumulated Depreciation | $-1,537,703,000 | $-1,454,110,000 | $-1,335,309,000 | $-1,161,130,000 |
| Gross PPE | $3,554,337,000 | $3,470,614,000 | $3,369,079,000 | $3,018,547,000 |
| Leases | $438,230,000 | $438,746,000 | $366,556,000 | $294,275,000 |
| Construction In Progress | $171,604,000 | $143,306,000 | $197,723,000 | $199,713,000 |
| Other Properties | $361,415,000 | $412,490,000 | $394,029,000 | $391,762,000 |
| Machinery Furniture Equipment | $1,413,494,000 | $1,334,669,000 | $1,277,310,000 | $1,110,888,000 |
| Buildings And Improvements | $1,097,572,000 | $1,069,667,000 | $1,053,915,000 | $963,717,000 |
| Land And Improvements | $72,022,000 | $71,736,000 | $79,546,000 | $58,192,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $169,401,000 | $183,718,000 | $278,236,000 | $168,550,000 |
| Work In Process | $88,743,000 | $51,785,000 | $59,727,000 | $48,367,000 |
| Raw Materials | $40,959,000 | $43,041,000 | $42,296,000 | $38,892,000 |
| Employee Benefits | - | - | - | - |
| Non Current Pension And Other Postretirement Benefit Plans | - | - | - | - |
| Non Current Deferred Revenue | - | - | - | - |
| Current Capital Lease Obligation | - | - | - | - |
| Defined Pension Benefit | - | - | - | - |
| Other Short Term Investments | - | - | - | - |
Fetched: 2026-07-08
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $518,494,000 | $501,610,000 | $365,370,000 | $294,907,000 |
| Operating Activities | ||||
| Operating Cash Flow | $737,646,000 | $734,577,000 | $683,898,000 | $619,640,000 |
| Cash Flow From Continuing Operating Activities | $737,646,000 | $734,577,000 | $683,898,000 | $619,640,000 |
| Operating Gains Losses | $21,535,000 | $13,569,000 | $-96,866,000 | $-96,630,000 |
| Investing Activities | ||||
| Capital Expenditure | $-219,152,000 | $-232,967,000 | $-318,528,000 | $-324,733,000 |
| Investing Cash Flow | $-209,321,000 | $-245,086,000 | $-563,155,000 | $-607,922,000 |
| Cash Flow From Continuing Investing Activities | $-209,321,000 | $-245,086,000 | $-563,155,000 | $-607,922,000 |
| Net Other Investing Changes | $3,364,000 | $4,549,000 | $-2,294,000 | $-9,347,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-360,673,000 | $-119,175,000 | $-24,155,000 | $-38,651,000 |
| Financing Cash Flow | $-536,726,000 | $-550,927,000 | $-85,521,000 | $-42,397,000 |
| Cash Flow From Continuing Financing Activities | $-536,726,000 | $-550,927,000 | $-85,521,000 | $-42,397,000 |
| Net Other Financing Charges | $-54,984,000 | $-43,442,000 | $-11,640,000 | $-48,650,000 |
| Net Common Stock Issuance | $-360,673,000 | $-119,175,000 | $-24,155,000 | $-38,651,000 |
| Other | ||||
| Repayment Of Debt | $-1,349,317,000 | $-1,493,769,000 | $-851,676,000 | $-2,932,636,000 |
| Issuance Of Debt | $1,227,534,000 | $1,081,581,000 | $776,353,000 | $2,952,430,000 |
| End Cash Position | $215,997,000 | $205,570,000 | $284,480,000 | $241,214,000 |
| Beginning Cash Position | $205,570,000 | $284,480,000 | $241,214,000 | $246,314,000 |
| Effect Of Exchange Rate Changes | $18,828,000 | $-17,474,000 | $8,044,000 | $25,579,000 |
| Changes In Cash | $-8,401,000 | $-61,436,000 | $35,222,000 | $-30,679,000 |
| Proceeds From Stock Option Exercised | $714,000 | $23,878,000 | $25,597,000 | $25,110,000 |
| Common Stock Payments | $-360,673,000 | $-119,175,000 | $-24,155,000 | $-38,651,000 |
| Net Issuance Payments Of Debt | $-121,783,000 | $-412,188,000 | $-75,323,000 | $19,794,000 |
| Net Long Term Debt Issuance | $-121,783,000 | $-412,188,000 | $-75,323,000 | $19,794,000 |
| Long Term Debt Payments | $-1,349,317,000 | $-1,493,769,000 | $-851,676,000 | $-2,932,636,000 |
| Long Term Debt Issuance | $1,227,534,000 | $1,081,581,000 | $776,353,000 | $2,952,430,000 |
| Net Investment Purchase And Sale | $-10,974,000 | $-11,189,000 | $-47,548,000 | $-153,725,000 |
| Sale Of Investment | $9,102,000 | $41,687,000 | $6,667,000 | $4,549,000 |
| Purchase Of Investment | $-20,076,000 | $-52,876,000 | $-54,215,000 | $-158,274,000 |
| Net Business Purchase And Sale | $17,441,000 | $-5,479,000 | $-194,785,000 | $-120,117,000 |
| Sale Of Business | $17,441,000 | $0 | $0 | $163,275,000 |
| Purchase Of Business | $0 | $-5,479,000 | $-194,785,000 | $-283,392,000 |
| Change In Working Capital | $14,081,000 | $-30,329,000 | $-102,380,000 | $-152,554,000 |
| Change In Other Working Capital | $-55,056,000 | $-26,870,000 | $1,335,000 | $121,355,000 |
| Change In Payables And Accrued Expense | $82,177,000 | $-41,875,000 | $-7,980,000 | $-44,816,000 |
| Change In Accrued Expense | $79,308,000 | $-27,604,000 | $12,447,000 | $-42,164,000 |
| Change In Payable | $2,869,000 | $-14,271,000 | $-20,427,000 | $-2,652,000 |
| Change In Account Payable | $2,869,000 | $-14,271,000 | $-20,427,000 | $-2,652,000 |
| Change In Inventory | $-48,777,000 | $16,804,000 | $-62,301,000 | $-78,523,000 |
| Change In Receivables | $35,737,000 | $21,612,000 | $-33,434,000 | $-150,570,000 |
| Other Non Cash Items | $2,504,000 | $33,251,000 | $1,079,000 | $16,118,000 |
| Stock Based Compensation | $71,083,000 | $69,891,000 | $72,048,000 | $73,617,000 |
| Provisionand Write Offof Assets | $6,062,000 | $14,774,000 | $18,225,000 | $6,706,000 |
| Asset Impairment Charge | $436,524,000 | $313,817,000 | $48,201,000 | $11,789,000 |
| Deferred Tax | $-75,292,000 | $-67,428,000 | $-50,903,000 | $-35,884,000 |
| Deferred Income Tax | $-75,292,000 | $-67,428,000 | $-50,903,000 | $-35,884,000 |
| Depreciation Amortization Depletion | $403,312,000 | $361,741,000 | $314,124,000 | $303,870,000 |
| Depreciation And Amortization | $403,312,000 | $361,741,000 | $314,124,000 | $303,870,000 |
| Earnings Losses From Equity Investments | $24,911,000 | $12,910,000 | $-97,827,000 | $26,775,000 |
| Gain Loss On Sale Of Business | $-3,376,000 | $659,000 | $961,000 | $-123,405,000 |
| Net Income From Continuing Operations | $-142,163,000 | $25,291,000 | $480,370,000 | $492,608,000 |
| Interest Paid Supplemental Data | - | $123,452,000 | $132,101,000 | $100,754,000 |
| Income Tax Paid Supplemental Data | - | $126,062,000 | $90,374,000 | $75,909,000 |
Fetched: 2026-07-08